Peroxisome proliferator-activated receptor γ (pparγ)- independent specific cytotoxicity against immature adipocytes induced by pparγ antagonist T0070907

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 9, 2013, Pages 1428-1434

  Kawahara, Arisa ^a   Haraguchi, Naoko ^a   Tsuchiya, Hiroyuki ^b   Ikeda, Yoshito ^a   Hama, Susumu ^a   Kogure, Kentaro ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Immature adipocyte; Oxidative stress; Peroxisome proliferator activated receptor ?; T0070907

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; ALPHA TOCOPHEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR GAL4;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANTI ADIPOGENIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; DRUG ACTIVITY; DRUG CONCENTRATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIPID STORAGE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; BENZAMIDES; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; GENES, REPORTER; MICE; NIH 3T3 CELLS; OXIDATIVE STRESS; PPAR GAMMA; PYRIDINES;

EID: 84884598614     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00024     Document Type: Article

References (22)

1. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, Nakamura M, Miao S, Cao P, Learned RM, Chen JL, Li Y. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem., 277, 19649-19657 (2002).
2. Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A, Saubermann LJ. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int. J. Cancer, 120, 702-713 (2007).
3. Burton JD, Castillo ME, Goldenberg DM, Blumenthal RD. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines. Anticancer Drugs, 18, 525-534 (2007).
4. Zaytseva YY, Wallis NK, Southard RC, Kilgore MW. The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms. Anticancer Res., 31, 813-823 (2011).
5. Ikeda Y, Hama S, Kajimoto K, Okuno T, Tsuchiya H, Kogure K. Quantitative comparison of adipocytokine gene expression during adipocyte maturation in non-obese and obese rats. Biol. Pharm. Bull., 34, 865-870 (2011).
6. Waku T, Shiraki T, Oyama T, Maebara K, Nakamori R, Morikawa K. The nuclear receptor PPARγ individually responds to serotoninand fatty acid-metabolites. EMBO J., 29, 3395-3407 (2010).
7. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev., 8, 1224-1234 (1994).
8. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Natl. Acad. Sci. U.S.A., 92, 7921-7925 (1995).
9. Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J. Biol. Chem., 277, 41925-41930 (2002).
10. Wakabayashi K, Okamura M, Tsutsumi S, Nishikawa NS, Tanaka T, Sakakibara I, Kitakami J, Ihara S, Hashimoto Y, Hamakubo T, Kodama T, Aburatani H, Sakai J. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Mol. Cell. Biol., 29, 3544-3555 (2009).
11. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 362, 1675-1685 (2010).
12. Landrier JF, Gouranton E, El Yazidi C, Malezet C, Balaguer P, Borel P, Amiot MJ. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology, 150, 5318-5325 (2009).
13. Uto-Kondo H, Ohmori R, Kiyose C, Kishimoto Y, Saito H, Igarashi O, Kondo K. Tocotrienol suppresses adipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J. Nutr., 139, 51-57 (2009).
14. Floyd ZE, Stephens JM. Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J. Biol. Chem., 277, 4062-4068 (2002).
15. Ohshima T, Koga H, Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J. Biol. Chem., 279, 29551-29557 (2004).
16. Yamashita D, Yamaguchi T, Shimizu M, Nakata N, Hirose F, Osumi T. The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells, 9, 1017-1029 (2004).
17. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell, 79, 1147-1156 (1994).
18. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol., 16, 2628-2644 (2.
19. Yoshida H, Yanai H, Ito K, Tomono Y, Koikeda T, Tsukahara H, Tada N. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis, 209, 520-523 (2010).
20. Hama S, Takahashi K, Inai Y, Shiota K, Sakamoto R, Yamada A, Tsuchiya H, Kanamura K, Yamashita E, Kogure K. Protective effects of topical application of a poorly soluble antioxidant astaxanthin liposomal formulation on ultraviolet-induced skin damage. J. Pharm. Sci., 101, 2909-2916 (2012).
21. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 114, 1752-1761 (2004).
22. Talior I, Tennenbaum T, Kuroki T, Eldar-Finkelman H. PKC-deltadependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. Am. J. Physiol. Endocrinol. Metab., 288, E405-E411 (2005).